Aligos Therapeutics, Inc.

DB:5WK0 Stock Report

Market Cap: €44.4m

Aligos Therapeutics Management

Management criteria checks 3/4

Aligos Therapeutics' CEO is Larry Blatt, appointed in Feb 2018, has a tenure of 6.58 years. total yearly compensation is $1.34M, comprised of 43.7% salary and 56.3% bonuses, including company stock and options. directly owns 1.39% of the company’s shares, worth €619.05K. The average tenure of the management team and the board of directors is 6.1 years and 3.4 years respectively.

Key information

Larry Blatt

Chief executive officer

US$1.3m

Total compensation

CEO salary percentage43.7%
CEO tenure6.6yrs
CEO ownership1.4%
Management average tenure6.1yrs
Board average tenure3.4yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Larry Blatt's remuneration changed compared to Aligos Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-US$76m

Mar 31 2024n/an/a

-US$100m

Dec 31 2023US$1mUS$587k

-US$88m

Sep 30 2023n/an/a

-US$82m

Jun 30 2023n/an/a

-US$82m

Mar 31 2023n/an/a

-US$83m

Dec 31 2022US$2mUS$549k

-US$96m

Sep 30 2022n/an/a

-US$112m

Jun 30 2022n/an/a

-US$126m

Mar 31 2022n/an/a

-US$136m

Dec 31 2021US$873kUS$549k

-US$128m

Sep 30 2021n/an/a

-US$125m

Jun 30 2021n/an/a

-US$125m

Mar 31 2021n/an/a

-US$116m

Dec 31 2020US$7mUS$493k

-US$109m

Sep 30 2020n/an/a

-US$92m

Jun 30 2020n/an/a

-US$73m

Mar 31 2020n/an/a

-US$62m

Dec 31 2019US$674kUS$475k

-US$52m

Compensation vs Market: Larry's total compensation ($USD1.34M) is above average for companies of similar size in the German market ($USD509.52K).

Compensation vs Earnings: Larry's compensation has been consistent with company performance over the past year.

CEO

Larry Blatt (62 yo)

6.6yrs

Tenure

US$1,344,458

Compensation

Dr. Lawrence M. Blatt, also known as Larry, Ph D., MBA, has been Chief Executive Officer and Director at Aligos Therapeutics, Inc. since February 2018 and also has been its Chairman of the Board since June...

Leadership Team

NamePositionTenureCompensationOwnership
Lawrence Blatt
CEO, President & Chairman of the Board6.6yrsUS$1.34m1.39%
$ 619.1k
Julian Symons
Executive VP & Chief Scientific Officer6.3yrsUS$836.32k0.26%
$ 113.5k
Lesley Calhoun
Executive VP & CFO4.3yrsno datano data
Kristina Engeseth
VP and Head of People & Culture2.7yrsno datano data
Sushmita Chanda
Executive Vice President & Chief Development Officer6.1yrsno datano data
David Smith
Executive VP & Head of Chemical Operations6.1yrsno datano data
Tse-I Lin
VP of Early Compound Development & Belgian Site Head2.7yrsno datano data

6.1yrs

Average Tenure

60yo

Average Age

Experienced Management: 5WK0's management team is seasoned and experienced (6.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Lawrence Blatt
CEO, President & Chairman of the Board6.6yrsUS$1.34m1.39%
$ 619.1k
Carole Nuechterlein
Independent Director6.1yrsUS$12.90kno data
K. Hirth
Independent Director6.1yrsUS$60.40k0.039%
$ 17.2k
James Scopa
Independent Director3.4yrsUS$67.90k0.12%
$ 52.7k
Heather Preston
Independent Directorless than a yearno datano data
Margarita Chavez
Independent Directorless than a yearno datano data
Bridget Martell
Independent Director2.8yrsUS$52.90kno data

3.4yrs

Average Tenure

62yo

Average Age

Experienced Board: 5WK0's board of directors are considered experienced (3.4 years average tenure).